1 The effect of combining antibiotics on resistance: A systematic 2 review and meta-analysis

- 3 Berit Siedentop^{1,2*}, Viacheslav N. Kachalov^{2,3}, Christopher Witzany¹, Matthias Egger^{4,5,6}, Roger D.
- 4 Kouyos^{2,3†}, Sebastian Bonhoeffer^{1*†}
- ⁵ ¹ Institute of Integrative Biology, Department of Environmental Systems Science, ETH Zürich,
- 6 Zurich, Switzerland
- ² Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University
 of Zürich, Zürich, Switzerland
- 9 ³ Institute of Medical Virology, University of Zurich, Zurich, Switzerland
- ⁴ Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
- ⁵ Population Health Sciences, University of Bristol, Bristol, UK
- ⁶ Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences,
- 13 University of Cape Town, Cape Town, South Africa
- 14 [†]These authors contributed equally
- 15 *Berit Siedentop, Sebastian Bonhoeffer
- 16 **Email:** berit.siedentop@env.ethz.ch, seb@env.ethz.ch

Author Contributions: SB, RDK, VNK, and BS conceived and designed the study. RDK and SB supervised the project. BS was responsible for the design of the literature search and the study protocol. VNK, RDK, SB, and ME reviewed the study protocol and approved it. VNK, CW, BS conducted the literature review, performed the data extraction. CW and BS assessed the quality of the studies. RDK, SB and BS conceptualised the statistical analysis. BS analysed the data. BS wrote the initial draft of the manuscript, which was revised by ME, RDK, CW and SB. All authors reviewed and approved the final version of the manuscript.

- 24 **Competing Interest Statement:** We declare no competing interests.
- 25 Keywords: antibiotic resistance, resistance evolution, combination therapy, meta-analysis,
- 26 systematic review
- 27

28

29 Abstract

30 When and under which conditions antibiotic combination therapy decelerates rather than

31 accelerates resistance evolution is not well understood. We examined the effect of combining

32 antibiotics on within-patient resistance development across various bacterial pathogens and

33 antibiotics.

34 We searched CENTRAL, EMBASE and PubMed for (quasi)-randomised controlled trials (RCTs)

35 published from database inception to November 24th, 2022. Trials comparing antibiotic treatments

36 with different numbers of antibiotics were included. A patient was considered to have acquired

37 resistance if, at the follow-up culture, a resistant bacterium (as defined by the study authors) was

38 detected that had not been present in the baseline culture. We combined results using a random

39 effects model and performed meta-regression and stratified analyses. The trials' risk of bias was

40 assessed with the Cochrane tool.

41 42 trials were eligible and 29, including 5054 patients, were qualified for statistical analysis. In

42 most trials, resistance development was not the primary outcome and studies lacked power. The

43 combined odds ratio (OR) for the acquisition of resistance comparing the group with the higher

44 number of antibiotics with the comparison group was 1.23 (95% CI 0.68-2.25), with substantial

45 between-study heterogeneity (I^2 = 77%). We identified tentative evidence for potential beneficial or

46 detrimental effects of antibiotic combination therapy for specific pathogens or medical conditions.

The evidence for combining a higher number of antibiotics compared to fewer from RCTs is
scarce and overall, is compatible with both benefit or harm. Trials powered to detect differences
in resistance development or well-designed observational studies are required to clarify the

50 impact of combination therapy on resistance.

51

52 Main Text

5354 Introduction

55 Antibiotics are one of the most significant advances in modern medicine, prescribed to treat 56 57 various bacterial infections in both humans and animals and prevent infections, such as surgical 58 site infections or opportunistic infections in immunocompromised individuals (1). However, this 59 medical breakthrough is at risk due to the rising prevalence of antibiotic resistance and an 60 inadequate pipeline of new antibiotics. This disturbing trend threatens to undermine the 61 effectiveness of antibiotics and poses a severe challenge to public health worldwide (2, 3). 62 Hence, we need a more prudent use of antibiotics, and where antibiotics are needed, we need 63 treatment strategies that reduce the risk that resistance emerges or spreads. Different strategies

2

for the optimal use of antibiotics have been investigated theoretically and empirically (4-7).
Antibiotic combination therapy, i.e., the simultaneous administration of several antibiotics, is
frequently discussed as a promising strategy for avoiding resistance evolution (6-10). Importantly,
it is the standard of care for some bacterial pathogens, such as *H. pylori*, *Mycobacterium tuberculosis* (Mtb), or *Mycobacterium leprae* (11-13). However, it is unclear whether the effect of
combination therapy on resistance is consistent for different pathogens.

70 There are several motivations for the use of antibiotic combination therapy, including to 71 broaden the antibiotic spectrum in empirical treatment and reducing antibiotic resistance 72 development (14, 15). The simultaneous occurrence of resistance mutations to multiple drugs is 73 less likely than resistance to single drugs. Combination therapy should, therefore, reduce the 74 development of resistance (10). This expectation is supported by viral infections such as HIV. 75 where multiple point mutations are required for resistance to combination antiviral therapy. 76 However, it is less clear to what extent this reasoning extends to antibiotic therapy, where the 77 same mechanism can facilitate bacterial survival against multiple antibiotics (16, 17), and where 78 horizontal transfer of resistance may occur. Indeed, the benefit of combining antibiotics for 79 reducing resistance is debated for bacterial infections (18). Using more antibiotics overall could 80 lead to more resistance, as overall antibiotic consumption correlates with resistance (19).

81 Two meta-analyses of randomised controlled trials (RCTs) comparing beta-lactam 82 monotherapy to beta-lactam and aminoglycoside combination therapy found no differences in 83 resistance development (4, 5). However, the effect of combining antibiotics on within-patient 84 resistance development across many bacterial pathogens and various antibiotic combinations has not been addressed. Within-patient antibiotic resistance development, even if rare, may 85 86 contribute to the emergence and spread of resistance. We performed a systematic review and 87 meta-analysis to (i) test the effect of antibiotic combination therapy on within-patient resistance 88 development and (ii) evaluate which factors affect the performance of combination therapy, as 89 e.g. pathogen identity, treatment design and resistance assessment.

90 Results

91 92 The search identified 3082 articles, which decreased to 1837 after deduplication. A total of 488 93 studies were eligible for full-text review, of which 41 studies qualified for inclusion. The screening 94 of the citations of the 41 studies identified one additional eligible study (SI section 11.4), for a total 95 of 42 studies, 40 RCTs and two quasi-RCTs, where the allocation method used is not truly 96 random (figure 1, table 1) (20-61). Twenty-nine studies could be included in the meta-analysis; 13 97 were excluded due to zero events in both treatment arms.

98 The included studies were published between 1977 and 2021, with a median publication 99 year of 1995 and few recent studies (figure 2 A). The development of antibiotic resistance was 100 typically not the main outcome: only nine studies (21%) explicitly defined a resistance outcome 101 (table 1, SI table S1). Consequently, most studies did not have the statistical power to detect 102 differences in within-patient resistance development even if we assume that the effect on 103 resistance development is large between treatment arms (figure 2 B, SI section 8). Twenty-two 104 (52%) focused on a specific pathogen species (resistant Acinetobacter baumannii, Escherichia 105 coli, H. pylori, Mtb, methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas 106 aeruginosa, Staphylococcus aureus) or pathogen group (MAC, Salmonella enterica subsp. 107 enterica serotype Thyphi, or Salmonella enterica subsp. enterica serotype Parthypi A).

108 The five most frequent reasons for antibiotic administration were treatment or prophylaxis 109 of urinary tract infections (UTIs) (6 studies, 14%), MRSA (5 studies, 12%), H. pylori, MAC, and 110 prophylaxis for hematological malignancy patients with four studies (10%) respectively. Twenty-111 three of the included studies (55%) compared treatment arms with at least one administered 112 antibiotic in common; the remaining studies compared treatment arms with no overlap in 113 administered antibiotics (table 1). For the outcome acquisition of resistance, only two of all 42 114 studies had a low overall risk of bias according to the risk of bias assessment. Twelve (29%) were at high risk of bias, 28 (67%) at moderate risk of bias (SI section 3). 115

116 The overall pooled OR for acquisition of resistance comparing a lower number of 117 antibiotics versus a higher one was 1.23 (95% CI 0.68 – 2.25), with substantial heterogeneity between studies (1²=77.4%). The latter OR was compatible with the OR for *de novo* emergence 118 119 of resistance (pooled OR 0.74, 95% Cl 0.34 – 1.59; l^2 =77%). The overall pooled estimates are 120 based on studies that focus on various clinical conditions/pathogens and compare different 121 antibiotics treatments. To explore the impact of these and other potential sources of 122 heterogeneity on the resistance estimates we performed sub-group analyses and meta-123 regression. The results for the two resistance outcomes are qualitatively comparable in the sense that individual estimates may differ, but show overall similar absence of evidence to support 124 125 either benefit, harm or equivalence of treating with a higher number of antibiotics. Therefore, our 126 focus in the following is on the acquisition of resistance (details on emergence of resistance can 127 be found in the SI sections 1-8).

128 Stratified analyses revealed that a higher number of antibiotics performed better than a 129 lower number in case of *H. pylori*, (pooled OR 0.14, 95% CI 0.03 – 0.55; l^2 =41.7%, figure 3A), 130 and *MAC* (pooled OR 0.18, 95% CI 0.06 – 0.52; l^2 =26.8%, figure 3A), but worse in case of *P.* 131 *aeruginosa* (pooled OR 3.42, 95% CI 1.03 – 11.43; l^2 =1.54%, figure 3A). Furthermore, a lower

4

132 number of antibiotics performed better than a higher number if the compared treatment arms had no antibiotics in common (pooled OR 4.73, 95% CI 2.14 – 10.42; l^2 =37%, SI table S3), which 133 134 could be due to different potencies or resistance prevalences of antibiotics as discussed in SI (SI 135 section 6.1.10). In contrast, when restricting the analysis to studies with at least one common 136 antibiotic in the treatment arms we found no evidence of a difference, only a weak indication that a higher number of antibiotics performs better (pooled OR 0.55, 95% CI 0.28 – 1.07; I^2 = 74%, 137 138 figure 3B). When considering only resistance measurements of antibiotics common to both 139 treatment arms instead of all resistance measurements, the arm with a higher number of 140 antibiotics shows a benefit in comparison to the one with fewer (pooled OR 0.39, 95% CI 0.18 -141 0.81: $I^2=75\%$. SI p 6). If the study measured the acquisition of resistance of both gram negative 142 and positive bacteria, fewer antibiotics performed better (pooled OR 3.38, 95% CI 1.08 - 10.58; l^2 =38,35%. SI p 5). Other sub-group analyses did not show any harm or benefit of using a higher 143 144 number of antibiotics. The results for all subgroup analyses are presented in the supplement (SI 145 section 6). The multi-model inference for our meta-regression showed that the only significant 146 factor influencing the outcome acquisition of resistance is whether at least one common antibiotic 147 was used in the comparator arms (for details see SI section 7).

148 The inspection of the funnel plot and the modified Egger's test showed no indication of a 149 publication bias (SI section 5). The results were largely robust to the choice of the random effects 150 model (SI section 4). The probability of the secondary outcome "alterations of the prescribed 151 treatment due to adverse events", was higher using more antibiotics in comparison to fewer 152 (pooled OR 1.61, 95% CI 1.12 – 2.31; l^2 =5%; SI p 10). In 15 studies (36%), the proportion of 153 patients with alterations of the prescribed treatment due to adverse events was reported, with 154 three studies (20%) reporting zero cases in both treatment arms. All other analyses of secondary 155 outcomes showed no indication of harm or benefit of treating with a higher number of antibiotics 156 (SI section 9).

157 Discussion

158

159 We performed a meta-analysis of RCTs and guasi-RCTs not limited to a particular 160 bacterial species, specific condition, or antibiotic combinations to assess the effect of antibiotic 161 combination therapy on within-patient resistance development. Our analysis could not identify any 162 benefit or harm of using a higher or a lower number of antibiotics regarding within-patient 163 resistance development. However, we found some evidence that combining antibiotics may be 164 beneficial or harmful for specific pathogens or infection types. Acquisition of resistance was rarely a primary objective of the included RCTs. Hence, they were typically not designed to detect 165 166 differences in resistance development between treatment arms and underpowered for this 167 endpoint. Therefore, the absence of evidence does not mean that there is convincing evidence

for the lack of an effect of using more or fewer antibiotics on resistance development but rather
highlights a knowledge gap. This is remarkable given that the general rise of resistance is an
increasing concern (3, 18) and a priority area for health policy and public health (62).

171 Our analysis showed that combining antibiotics reduced resistance development for H. 172 pylori or MAC, in line with the current standard of care (11, 63). Surprisingly, we found only two 173 studies that satisfied our inclusion criteria for Mtb (24, 40), which may be considered the prime 174 example of effective antibiotic combination therapy. The limited number of Mtb studies may be 175 because antibiotic administration commonly varies during Mtb treatment, which conflicted with our 176 inclusion criteria that necessitated a consistent treatment regimen for susceptibility 177 measurements (SI section 2). Both eligible Mtb studies were excluded from the analysis due to 178 the absence of any events in either treatment arm.

179 Our main result, the absence of a general effect of combining antibiotics on resistance 180 development, aligns with the two previous meta-analyses (4, 5). With 42 trials in our systematic 181 review and 29 in the meta-analysis, our study provided a comprehensive assessment of the effect 182 of antibiotic combination therapy on within-patient resistance. Whereas previous meta-analyses 183 focused on a combination of specific antibiotic classes and included fewer than ten studies each, 184 our study aimed to assess the general effect of combining antibiotics on resistance evolution 185 across different bacterial pathogens. By including trials with different antibiotic combinations and 186 bacterial pathogens, we increased clinical and statistical heterogeneity. We accounted for many 187 sources of heterogeneity using stratification and meta-regression, but analyses were limited by 188 missing information and sparse data.

189 Our findings have implications for the design of future studies of resistance development. 190 Generally, the development of resistance within a patient is a rare event. However, even small 191 differences could be relevant at the population level. To obtain reliable estimates of such 192 differences and to better understand the factors influencing them, very large RCTs would be 193 needed, which systematically investigate the development of antibiotic resistance and include 194 resistance testing of each administered antibiotic. 19 (45%) of our included studies compared 195 treatment arms with no antibiotics in common, and 22 studies (52%) had more than one antibiotic 196 not identical in the treatment arms (table 1). To better evaluate the effect of combination therapy, 197 especially more RCTs would be needed where the basic antibiotic treatment is consistent across 198 both treatment arms, i.e. the antibiotics used in both treatment arms should be identical, except 199 for the additional antibiotic added in the comparator arm (table 1). As such RCTs are costly and 200 associated with high hurdles, the analysis of cohort studies could be an alternative approach. 201 Over 25 years ago, Fish et al. published a systematic summary of prospective observational

studies reporting data on resistance development, including antibiotic combination therapy (64).
Similarly, today, relevant cohort studies could be analysed collaboratively using various modern
statistical methods to address confounding by indication and other biases (65, 66). However,
even with appropriate causal inference methods, residual confounding cannot be excluded when
using observational data (67). Therefore, RCTs will remain the gold standard to estimate causal
relationships.

208 The main strength of this study is its comprehensive and systematic approach. For one, it 209 allowed identifying a knowledge gap regarding the effect of antibiotic combination therapy on 210 resistance development. Further, our study highlights several issues in the evidence base 211 evaluating antibiotic combination therapy and resistance development. The included trials did not 212 always test and report systematically the susceptibility against all administered antibiotics (table 213 1). Some antibiotics might have had reduced potency or were ineffective due to pre-existing 214 resistance mutations. Furthermore, in studies where treatment was not targeted against a specific 215 pathogen, some antibiotics may have been inactive against the causative pathogen due to 216 intrinsic resistance. Indeed, one of the reasons for using combination therapy is to broaden the 217 bacterial spectrum for empirical therapy (15), which could contribute to an increased risk of 218 antibiotic resistance spread.

219 Our study had several limitations. First, despite our systematic search, we might have 220 missed relevant studies. Since resistance development is typically not a primary endpoint and 221 often not reported systematically, relevant trials are challenging to identify. Our search strategy 222 aimed to identify a broad range of trials considering resistance development. However, as a 223 trade-off, our search strategy might have missed trials addressing a specific medical condition or 224 drug combination. Second, our systematic review and meta-analysis included many older studies 225 that did not follow the relevant reporting guidelines (68), thereby hampering data extraction and 226 potentially introducing bias. Third, it is often challenging to discern the specific mechanisms by 227 which resistance develops based on the data from clinical trials. This includes distinguishing 228 whether resistance arises de novo, if the pathogen acquires resistance through horizontal gene 229 transfer, if the patient becomes newly infected with a resistant pathogen, or if the pathogen was 230 present but undetected at the beginning of treatment. These scenarios can impact the 231 effectiveness of combination therapy. For example, combination therapy may be more likely to 232 select any pre-existing resistant pathogens compared to monotherapy due to the use of multiple 233 antibiotics. We addressed some of this heterogeneity by employing two different measures of 234 resistance (SI section 1). Furthermore, the variation in standards that classify bacteria as 235 susceptible or resistant adds another layer of heterogeneity alongside the technical limitations in 236 detecting resistance development.

237 In conclusion, combination therapy offers potential advantages and disadvantages 238 regarding resistance evolution and spread. On the one hand, combination therapy typically 239 increases the genetic barrier to resistance, and it has become the standard therapy for pathogens 240 notorious for resistance evolution. Therefore, combination therapy remains a plausible candidate 241 strategy to slow down resistance evolution. On the other hand, combination therapy generates 242 selection pressure for resistance to multiple antibiotics simultaneously and could, therefore, 243 accelerate resistance evolution - especially in the microbiome. Given the critical nature of this 244 context, it is profoundly disconcerting that there is a lack of evidence elucidating the impact of 245 combining antibiotics on the development of resistance.

246 Materials and Methods

247

248 Inclusion criteria and search strategy

249 We did a systematic review and meta-analysis to summarise the evidence on the effect of 250 antibiotic combination therapy on resistance development. We included RCTs and quasi-RCTs 251 comparing treatments with a higher number of antibiotics to treatments with a lower number of 252 antibiotics. Studies were classified as quasi-RCTs if the allocation of participants to study arms 253 was not truly random. We did not consider antiseptics or compounds supporting the activity of 254 antibiotics, such as beta-lactam inhibitors as antibiotics itself. Whereas the antibiotic substances 255 administered within one treatment arm had to be the same for all patients, the antibiotics could 256 differ between treatment arms. We required baseline and follow-up cultures with resistance 257 measurements to determine the treatment impact on resistance. We considered only antibiotic 258 treatment regimens fixed for the period between two resistance measurements. Hence, we 259 excluded sequential and cycling regimens.

260 We searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials 261 (CENTRAL) from inception up to 24.11.2022, using keywords, medical subject headings (MeSH), 262 and EMTREE terms related to bacterial infection, antibiotics, combination therapy, resistance and 263 RCTs. We excluded complementary and alternative medicine and bismuth. The search strategy 264 is detailed in the SI (section 11). After a systematic deduplication process (69), VNK (or CW) and 265 BS independently screened the titles and abstracts, and, if potentially eligible, the full texts. Any 266 discrepancies between VNK (or CW) and BS were discussed and resolved. At full-text screening, 267 we excluded articles that were not accessible in English or German. We screened the references 268 of eligible studies and the trials included in two previous meta-analyses (4, 5). We followed the 269 PRISMA reporting guidelines (70) and registered our protocol with PROSPERO 270 (CRD42020187257).

271

8

272 Outcomes

273 We used two definitions for the primary outcome resistance. A broader definition, "acquisition of 274 resistance", and a stricter "de novo emergence of resistance" definition, where the latter is a 275 subset of the former. A patient was considered to have acquired resistance if, at the follow-up 276 culture, a resistant bacterium (as defined by the study authors) was detected that was not present 277 in the baseline culture. De novo emergence of resistance was defined as the detection of a 278 resistant bacterium that was present at baseline but sensitive. Additional secondary outcomes 279 included mortality from all causes and infection, treatment failure overall, treatment failure due to 280 resistance, treatment change due to adverse effects, and acquisition/de novo emergence of 281 resistance against non-administered antibiotics. The SI (section 9) provides further details.

282 Data extraction and analysis

VNK (or CW) and BS independently extracted all study data using a standardised form (see
 https://osf.io/gwefy/?view_only=f6a4c1f4c79241038b203bd03c8e1845). The data extracted
 included the proportion of patients who developed the two primary outcomes and the secondary
 outcomes and study characteristics such as type of trial (RCT or quasi-RCT), follow-up and
 treatment duration, number of antibiotics in the treatment arms, type of antibiotic, and presence of
 comorbidities. Any discrepancies in data extraction were discussed and resolved.

289 We calculated odds ratios (ORs) with 95% confidence intervals (CIs), comparing a higher 290 with a lower number of antibiotics for each study. We combined ORs using a modified version of 291 the Simmonds and Higgins random effects model (71). If a study had more than two eligible 292 treatment arms, they were merged for statistical analysis. Studies with zero events in both 293 treatment arms were excluded from the statistical analysis. We used subgroup analyses and 294 meta-regressions with multi-model inference to examine the influence of pre-specified variables 295 on summary ORs. Variables included whether the antibiotic(s) used in the arm with the lower 296 number of antibiotics are also part of the arm(s) with the higher number of antibiotics, the number 297 of antibiotics administered, the age of the antibiotics (time since market entry), the administration 298 of other non-antibiotic drugs, whether participants had specific comorbidities or were in intensive 299 care, gram-status of the tested pathogens, and the length of antibiotic treatment and follow-up. 300 We extended our predefined analysis regarding the reason for antibiotic treatment/type of 301 pathogen, which was initially restricted to only H. pylori and Mtb, as we found enough studies to 302 stratify by other conditions/pathogens. We furthermore performed post-hoc subgroup analyses to 303 examine the following factors: treatment of resistant pathogens, additional antibiotic 304 administration besides the fixed treatment, and the way of antibiotic administration (SI section 305 6.2).

- Between study heterogeneity was estimated with I^2 , using the criteria for I^2 specified in
- 307 Higgins et al. for classifying the degree of heterogeneity (72). CW and BS assessed each study's
- 308 quality for the main outcomes using the Risk of Bias tool (RoB 2, SI section 3) (73). To assess
- 309 publication bias, we visually inspected the funnel plot and a modified Egger's test (SI section 5).
- 310 We performed sensitivity analyses on the model choice (SI section 4.1), and risk of bias (SI
- section 4.2), and performed a post-hoc trial sequential analysis (SI section 8.3). Statistical
- analyses and visualisations were done in R (version 4.2.1) using packages metafor and MuMIn
- 313 (74, 75).

314 Acknowledgments

Support from the Swiss National Science Foundation (grant 310030B_176401 (SB, BS, CW),
grant 32FP30-174281 (ME), grant 324730_207957 (RDK)) and from the National Institute of
Allergy and Infectious Diseases (NIAID, cooperative agreement AI069924 (ME)) is gratefully
acknowledged. We thank Anthony Hauser, João Pires and Frédérique Lachmann for helpful
discussions and Annelies Zinkernagel and Johannes Nemeth for critical reading of the

- 321 manuscript. Furthermore, we are grateful for all contacted study authors that responded to our
- inquiries and provided further information.

323 References

324

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial
 Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical
 Practice Guideline Update. Journal of Clinical Oncology. 2018;36(30):3043-54.

Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Current
 Opinion in Microbiology. 2019;51:72-80.

Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden
 of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet.
 2022;399(10325):629-55.

Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of
 Aminoglycoside and β-Lactam Combination Therapy versus β-Lactam Monotherapy on the
 Emergence of Antimicrobial Resistance: A Meta-analysis of Randomized, Controlled Trials.
 Clinical Infectious Diseases. 2005;41(2):149-58.

Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy
 versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane
 Database of Systematic Reviews. 2014(1).

Angst DC, Tepekule B, Sun L, Bogos B, Bonhoeffer S. Comparing treatment strategies to
reduce antibiotic resistance in an in vitro epidemiological setting. Proceedings of the National
Academy of Sciences. 2021;118(13):e2023467118.

Tepekule B, Uecker H, Derungs I, Frenoy A, Bonhoeffer S. Modeling antibiotic treatment
in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing,
and mono-drug therapies. PLOS Computational Biology. 2017;13(9):e1005745.

3468.Sullivan GJ, Delgado NN, Maharjan R, Cain AK. How antibiotics work together: molecular347mechanisms behind combination therapy. Current Opinion in Microbiology. 2020;57:31-40.

Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the
 21st century. Nature Reviews Microbiology. 2019;17(3):141-55.

350 10. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic 351 resistance. Proceedings of the National Academy of Sciences. 1997;94(22):12106-11. 352 De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for 11. 353 Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol. 354 2017;30(4):373-9. 355 12. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on 356 drug resistance in Mycobacterium tuberculosis. Journal of Applied Microbiology. 357 2020;128(6):1547-67. 358 13. Alemu Belachew W, Naafs B. Position statement: LEPROSY: Diagnosis, treatment and 359 follow-up. Journal of the European Academy of Dermatology and Venereology. 360 2019;33(7):1205-13. 361 Pletz MW, Hagel S, Forstner C. Who benefits from antimicrobial combination therapy? 14. The Lancet Infectious Diseases. 2017;17(7):677-8. 362 363 15. Roemhild R, Bollenbach T, Andersson DI. The physiology and genetics of bacterial 364 responses to antibiotic combinations. Nature Reviews Microbiology. 2022. 365 Du D, Wang-Kan X, Neuberger A, van Veen HW, Pos KM, Piddock LIV, et al. Multidrug 16. 366 efflux pumps: structure, function and regulation. Nature Reviews Microbiology. 2018;16(9):523-367 39. 368 17. Lázár V, Snitser O, Barkan D, Kishony R. Antibiotic combinations reduce Staphylococcus 369 aureus clearance. Nature. 2022;610(7932):540-6. 370 Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. 18. 371 Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet. 372 2016;387(10014):176-87. 373 Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in 19. 374 Europe and association with resistance: a cross-national database study. The Lancet. 375 2005;365(9459):579-87. 376 20. Bender JF, Schimpff SC, Young VM, Fortner CL, Brouillet MD, Love LJ, et al. Role of 377 vancomycin as a component of oral nonabsorbable antibiotics for microbial suppression in 378 leukemic patients. Antimicrobial agents and chemotherapy. 1979;15(3):455-60. 379 Black RE, Levine MM, Clements ML, Cisneros L, Daya V. Treatment of experimentally 21. 380 induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-381 sulfamethoxazole, or placebo. Reviews of infectious diseases. 1982;4(2):540-5. 382 Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, et al. Clarithromycin and 22. 383 ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium 384 complex disease in patients with HIV infection. AIDS (london, england). 1997;11(3):311-7. 385 23. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective 386 randomized comparison of imipenem monotherapy with imipenem plus netilmicin for 387 treatment of severe infections in nonneutropenic patients. Antimicrobial agents and 388 chemotherapy. 1994;38(6):1309-13. 389 Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency 24. 390 and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during 391 the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial 392 in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet (london, 393 england). 2015;385(9979):1738-47.

25. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a
 comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Annals of internal
 medicine. 1987;106(1):7-11.

26. Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, et al.
Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs.
Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2019.

Dubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, et al. A randomized
evaluation of ethambutol for prevention of relapse and drug resistance during treatment of
Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy.
Journal of Infectious Diseases. 1997;176(5):1225-32.

28. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al.
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due
to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
Clinical infectious diseases. 2013;57(3):349-58.

410 29. Fournier S, Burguière AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M. Effect of
411 adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium
412 complex septicemia in AIDS patients. European journal of clinical microbiology & infectious
413 diseases. 1999;18(1):16-22.

Gerecht WB, Henry NK, Hoffman WW, Muller SM, LaRusso NF, Rosenblatt JE, et al.
Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and
gentamicin therapy for patients with cholangitis. Archives of internal medicine.
1989;149(6):1279-84.

Gibson J, Date L, Joshua DE, Young GA, Wilson A, Benn R, et al. A randomised trial of
empirical antibiotic therapy in febrile neutropenic patients with hematological disorders:
ceftazidime versus azlocillin plus amikacin. Australian and new zealand journal of medicine.
1989;19(5):417-25.

422 32. Haase DA, Harding GK, Thomson MJ, Kennedy JK, Urias BA, Ronald AR. Comparative trial
423 of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized,
424 acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal
425 microflora. Antimicrobial agents and chemotherapy. 1984;26(4):481-4.

426 33. Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B, Olearo F, et al.
427 Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin
428 versus linezolid for the treatment of MRSA infection. Journal of antimicrobial chemotherapy.
429 2015;70(1):264-72.

430 34. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC. Oral ciprofloxacin compared
431 with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with
432 cystic fibrosis. Lancet (london, england). 1987;1(8527):235-7.

433 35. Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparative study of ceftriaxone
434 monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of
435 serious bacterial infections: the efficacy, safety and effect on fecal flora. Chemotherapy. 1988;34
436 Suppl 1:21-9.

437 36. Hultén K, Jaup B, Stenquist B, Engstrand L. Combination treatment with ranitidine is 438 highly efficient against Helicobacter pylori despite negative impact of macrolide resistance.

439 Helicobacter. 1997;2(4):188-93.

440 37. Iravani A, Richard GA, Baer H, Fennell R. Comparative efficacy and safety of nalidixic acid
441 versus trimethoprim/sulfamethoxazole in treatment of acute urinary tract infections in college442 age women. Antimicrobial agents and chemotherapy. 1981;19(4):598-604.

44338.Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL. Ceftazidime versus444ceftazidime plus tobramycin in febrile neutropenic children. Infection. 1993;21(4):223-8.

39. Jo JH, Harkins CP, Schwardt NH, Portillo JA, Zimmerman MD, Carter CL, et al. Alterations
of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.
Sci Transl Med. 2021;13(625):eabd8077.

448 40. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater,
449 versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. South African
450 medical journal. 1994;84(6):325-8.

41. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with
vancomycin for the treatment of Staphylococcus aureus infection. Annals of internal medicine.
1992;117(5):390-8.

454 42. Mavromanolakis E, Maraki S, Samonis G, Tselentis Y, Cranidis A. Effect of norfloxacin,
455 trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent
456 urinary tract infections. Journal of chemotherapy (florence, italy). 1997;9(3):203-7.

43. May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, et al. Comparison of
combination therapy regimens for treatment of human immunodeficiency virus-infected
patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium
Group. Agence Nationale de Recherche sur le Sida. Clinical infectious diseases. 1997;25(3):6219.

462 44. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. Comparison of
463 piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in
464 children with cystic fibrosis. Pediatric pulmonology. 1988;4(4):201-4.

465 45. Menon R, Roberts FE, Barr KW, Howard H, Lord VL, Hegarty MA, et al. Comparison of a
466 slow-release trimethoprim with co-trimoxazole: efficacy and selection of resistance in the
467 Enterobacteriaceae. Journal of antimicrobial chemotherapy. 1986;18(3):415-20.

468 46. Miehlke S, Meining A, Lehn N, Höchter W, Weingart J, Simon T, et al. Comparison of
469 omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for
470 the cure of Helicobacter pylori infection. Digestion. 1998;59(6):646-50.

47. Parras F, Guerrero MC, Bouza E, Blázquez MJ, Moreno S, Menarguez MC, et al.
472 Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication
473 of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrobial agents and
474 chemotherapy. 1995;39(1):175-9.

475 48. Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR. Treatment of
476 pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and
477 gentamicin. J Pediatr. 1977;90(1):144-8.

478 49. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, Tung le T, et al. Randomized controlled
479 comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for
480 treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrobial agents
481 and chemotherapy. 2007;51(3):819-25.

482 50. Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, Ghanem-Zoubi N, et al.

483 Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin

resistant Staphylococcus aureus: randomised controlled trial. BMJ (clinical research ed).
2015;350:h2219.

Pogue JM, Rybak MJ, Stamper K, Marchaim D, Thamlikitkul V, Carmeli Y, et al.
Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with
Meropenem. Open Forum Infectious Diseases. 2021;8(SUPPL 1):S418-S9.
52. Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, et al. Daptomycin
Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus
Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin Infect Dis. 2021;72(9):1517-25.

491 Dacterenna and Endocarditis: A Randomized Clinical That. Clinimect Dis. 2021, 72(5):15
 492 53. Rubinstein E, Lode H, Grassi C, Castelo A, Ward K, Alanko K, et al. Ceftazidime
 493 monotherapy vs. Ceftriaxone/tobramycin for serious hospital- acquired gram-negative
 494 infections. Clinical Infectious Diseases. 1995;20(5):1217-28.

495 54. Schaeffer AJ, Flynn S, Jones J. Comparison of cinoxacin and trimethoprim496 sulfamethoxazole in the treatment of urinary tract infections. Journal of urology.
497 1981;125(6):825-7.

498 55. Schaeffer AJ, Sisney GA. Efficacy of norfloxacin in urinary tract infection biological 499 effects on vaginal and fecal flora. Journal of urology. 1985;133(4):628-30.

500 56. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, et al. Comparison of a
 501 β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic
 502 fibrosis. Journal of Pediatrics. 1999;134(4):413-21.

57. Stack WA, Knifton A, Thirlwell D, Cockayne A, Jenkins D, Hawkey CJ, et al. Safety and
efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of
Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. American
journal of gastroenterology. 1998;93(10):1909-13.

507 58. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized
508 double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole
509 against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial
510 resistance and effect of host factors on outcome. Antimicrobial agents and chemotherapy.
511 1993;37(6):1334-42.

512 59. Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus
513 vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med.
514 1986;80(5):884-90.

515 60. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus
516 vancomycin/polymyxin for prevention of infections in granulocytopenic patients. American
517 journal of medicine. 1990;88(1):36-42.

61. Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, et al. Shortcourse therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates
Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Alimentary pharmacology &
therapeutics. 1997;11(5):943-52.

522 62. Joshi LT. The G7 Summit 2021: time for our world leaders to step up to the challenge of 523 antimicrobial resistance. Access Microbiology. 2021;3(12).

524 63. Kerantzas Christopher A, Jacobs William R, Rubin Eric J, Collier RJ. Origins of
525 Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and
526 Application. mBio.8(2):e01586-16.

527 64. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial

528 therapy: a review of antibiotic classes and patient characteristics in 173 studies.

529 Pharmacotherapy. 1995;15(3):279-91.

530 65. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference
531 From Observational Data. JAMA. 2022;328(24):2446-7.

532 66. Hernán MA. Methods of Public Health Research — Strengthening Causal Inference from
533 Observational Data. New England Journal of Medicine. 2021;385(15):1345-8.

534 67. Schuster NA, Rijnhart JJ, Bosman LC, Twisk JW, Klausch T, Heymans MW.

535 Misspecification of confounder-exposure and confounder-outcome associations leads to bias in 536 effect estimates. BMC medical research methodology. 2023;23(1):11.

537 68. Schulz KF, Altman DG, Moher D, for the CG. CONSORT 2010 Statement: Updated
538 Guidelines for Reporting Parallel Group Randomised Trials. PLOS Medicine. 2010;7(3):e1000251.
539 69. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database

539 69. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of data 540 search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240-3.

70. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic
 Reviews. 2021;10(1):89.

544 71. Jackson D, Law M, Stijnen T, Viechtbauer W, White IR. A comparison of seven random-545 effects models for meta-analyses that estimate the summary odds ratio. Stat Med.

546 2018;37(7):1059-85.

547 72. Deeks JJ, Higgins JPT, Altman DG. Analysing Data and Undertaking Meta-Analyses.

548 Chichester, UK: John Wiley & Sons, Ltd; 2008. p. 243-96.

54973.Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised550tool for assessing risk of bias in randomised trials. BMJ. 2019;366:14898.

551 74. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. Journal of

- 552 Statistical Software. 2010;36(3):1 48.
- 553 75. Bartoń K. MuMIn: Multi-Model Inference. 2020.

554

Figures and Tables




Figure 1. Study selection




Figure 2. Measuring antibiotic resistance is not a current main objective of RCTs. A) Distribution of the publishing year of included studies, where n indicates the number of studies, and the red vertical line the median of the distribution. B) Calculated power of included studies to detect an odds ratio of 0.5. The power calculations were based on equal treatment arm sizes. For the calculations the treatment arm with the higher number of patients of the respective studies was used.

| - | Antibio | otics | | biotics compared 2 vs. 3 3 vs. 4 | D | | | | | ntibiotics compared |
|---|-------------------------|------------------------|-----------------------|--|---|--------------------------------|-----------------------|---------------|-------------|--|
| Study / Subgroup | Less (n/N) | More (n/N) | OR (95% CI) | OR (95% CI) | Study / subgroup | Antibio Less (n/N) | tics More (n/N) | OR (95% | | 2 vs. 3 🖬 3 vs. 4 OR (95% C |
| ודו | | | | | MAC | . , | . , | | | |
| avani 1981 ³⁷ | 0/65 | 0/58 | | | Fournier 1999 ²⁹ Dubé 1997 ²⁷ | 0 / 16 16 / 35 | 0 / 18 11 / 45 | - | | 0.38 (0.15 to 0.99 |
| Schaeffer 1981 ⁵⁴ laase 1984 ³² | 0 / 15 0 / 21 | 3 / 15 3 / 21 | | 8.68 (0.41 to 184.28) 8.14 (0.39 to 167.98) | Chaisson 1997 ²² May 1997 ⁴³ | 1 / 48 21 / 67 | 0/41 2/67 | | _ | 0.38 (0.02 to 9.62 |
| Schaeffer 198555 | 0 / 20 | 2/19 | | 5.86 (0.26 to 130.36) | RE Model for Subgroup (I | | | _ | | 0.07 (0.02 to 0.30 0.18 (0.06 to 0.52 |
| lavromanolakis 1997 ⁴² lenon 1986 ⁴⁵ | 1 / 14 13 / 71 | 1 / 7 13 / 65 | | 2·17 (0·12 to 40·81) 1·12 (0·47 to 2·62) | H. pylori | | , | - | | 0.10 (0.00 10.000 |
| RE Model for Subgroup (I ² = 28. | | | | 3·35 (0·67 to 16·71) | Hultén 1997 ³⁶ Stack 1998 ⁵⁷ | 4 / 53 3 / 18 | 3 / 52 0 / 35 | | - | 0.75 (0.16 to 3.53 0.06 (0.00 to 1.28 |
| IRSA | 0,0,1 = 0 | 51) | | 0 00 (0 07 10 1071) | Wurzer 1997 ⁶¹ | 26 / 104 | 2/102 | | | 0.06 (0.01 to 0.26 |
| arras 199547 | 0/37 | 0/36 | | | RE Model for Subgroup (l | $r^2 = 41.7\%, \ \tau^2 = 0.6$ | 4) | - | | 0.14 (0.03 to 0.55 |
| larbarth 2015 ³³ | 0 / 69 3 / 45 | 0 / 68 9 / 49 | | 3.15 (0.80 to 12.48) | P. aeruginosa Mc Carty 1988 ⁴⁴ | 0/8 | 0/9 | | | |
| Valsh 199358 Paul 201550 | 0/117 | 1/135 | | 2.62 (0.11 to 64.95) | Smith 199956 | 2/30 | 11 / 40 | - | • | 5.31 (1.08 to 26.13 |
| Pujol 2021 ⁵² | 1/81 | 0/74 | | 0.36 (0.01 to 8.98) | MRSA Walsh 1993 ⁵⁸ | 3/45 | 9 / 49 | L | - | 3.15 (0.80 to 12.48 |
| RE Model for Subgroup ($I^2 = 1.2$ | | | - | 2.53 (0.73 to 8.80) | Walsh 1993 ⁵⁸ Pujol 2021 ⁵² | 1/81 | 0/74 | | _ | 0.36 (0.01 to 8.98 |
| Prophylaxis for hematological | malignan 2 / 36 | cy patients 14 / 30 | | 14.99 (9.01 to 79.40) | RE Model for Subgroup (I | $t^2 = 41.7\%, \ \tau^2 = 0.6$ | 4) | - | - | 2.28 (0.64 to 8.10 |
| Vinston 1986 ⁵⁹ Vinston 1990 ⁶⁰ | 2/30 | 9/32 | | 14.88 (3.01 to 73.40) 5.48 (1.08 to 27.92) | Macnab 1994 ⁴⁰ | 0 / 173 | 0/146 | | | |
| 0ekker 1987 ²⁵ | 7 / 28 4 / 20 | 10 / 28 3 / 18 | - | 1.67 (0.53 to 5.28) | Dawson 2015 ²⁴ | 0/118 | 0 / 59 | | | |
| ender 1979 ²⁰ RE Model for Subgroup (I ² = 49∙ | | | | 0.80 (0.15 to 4.18) | UTI Menon 1986 ⁴⁵ | 13/71 | 13 / 65 | - | | 1.12 (0.47 to 2.62 |
| | 1%, 1 = 0 | 55) | - | 3·26 (1·18 to 9·02) | Resistant A. baumannii | | | | | |
| <i>IAC</i> ournier 1999 ²⁹ | 0/16 | 0/18 | | | Durante-Mangoni 201328 | 0 / 105 | 0 / 104 | | | |
|)ubé 1997 ²⁷ | 16/35 | 11/45 | - | 0.38 (0.15 to 0.99) | Pulmanory infection Parry 1977 ⁴⁸ | 7/14 | 7/14 | - | _ | 1.00 (0.23 to 4.40 |
| Chaisson 1997 ²² Nay 1997 ⁴³ | 1 / 48 21 / 67 | 0/41 2/67 | | 0.38 (0.02 to 9.62) 0.07 (0.02 to 0.30) | Prophylaxis for hematol | logical malignanc | | | | |
| RE Model for Subgroup (I ² = 26. | | | - | 0.18 (0.06 to 0.52) | Bender 1979 ²⁰ Pneumonia, sepsis, peri | 4 / 20 | 3/18 | - | - | 0.80 (0.15 to 4.18 |
| l. pylori | | , | • | | Cometta 1994 ²³ | 8 / 142 | 13 / 138 | + | - | 1.74 (0.70 to 4.34 |
| liehlke 199846 | 0 / 73 | 0 / 78 | | | Neutropenia | 2/45 | 2/44 | | | 1 00 (0 11 1 7 0 |
| lultén 1997 ³⁶ Stack 1998 ⁵⁷ | 4 / 53 3 / 18 | 3 / 52 0 / 35 | | 0.75 (0.16 to 3.53) 0.06 (0.00 to 1.28) | Jacobs 1993 ³⁸ Multidrug resistant typh | | 2/44 | | _ | 1.02 (0.14 to 7.61 |
| Vurzer 1997 ⁶¹ | 26 / 104 | 2 / 102 | | 0.06 (0.01 to 0.26) | Parry 200749 | 0 / 125 | 0 / 67 | | | |
| RE Model for Subgroup (I ² = 41· | 7%, τ ² = 0· | 64) | - | 0.14 (0.03 to 0.55) | Gram-negative resistan Pogue 2021 ⁵¹ | nt BSI, pneumonia 23 / 191 | 16 / 189 | | | 0.68 (0.34 to 1.32 |
| P. aeruginosa | | | | | E. coli | 207101 | 107 100 | 1 | | 0 00 (0 04 10 1 02 |
| Ac Carty 1988 ⁴⁴ Smith 1999 ⁵⁶ | 0/8 2/30 | 0/9 11/40 | | 5.31 (1.08 to 26.13) | Black 1982 ²¹ | 5 / 10 | 0/10 | | | 0.05 (0.00 to 1.03 |
| lodson 1987 ³⁴ | 2/20 | 3 / 20 | | 1.59 (0.24 to 10.70) | Carpenem resistant infe Dickstein 2020 ²⁶ | ections 10 / 106 | 12 / 108 | - | | 1.20 (0.49 to 2.91 |
| RE Model for Subgroup (I ² = 1.5 | %, τ ² = 0·0 | 1) | • | 3·42 (1·03 to 11·34) | Total (95% CI) | 149 / 1625 | | | | 0.55 (0.28 to 1.07 |
| leutropenia | | | | | Heterogeneity: r ² =1.25; l ² : | | | antibiotics F | avors fewer | |
| acobs 1989 ³¹ acobs 1993 ³⁸ | 0 / 52 2 / 45 | 0 / 50 2 / 44 | | 1.02 (0.14 to 7.61) | | | ſ | | | |
| Actuberculosis | 2745 | 2/44 | | 1.02 (0.14 (0 7.01) | | | | 0.04 1 | 25.70 | |
| Aacnab 1994 ⁴⁰ | 0 / 173 | 0 / 146 | | | | | | | 2070 | |
| awson 2015 ²⁴ | 0/118 | 0 / 59 | | | | | | | | |
| Skin microbiota of healthy vol o 2021 ³⁹ | unteers 6/8 | 3/3 | | 0.60 (0.10 to 79.00) | | | | | | |
| Serious bacterial infection | 070 | 575 | | 2.69 (0.10 to 73.20) | | | | | | |
| loepelman 1988 ³⁵ | 0 / 48 | 9/44 | | -25.96 (1.46 to 460.84) | | | | | | |
| S. aureus | | | | | | | | | | |
| Markowitz 1992 ⁴¹ | 0 / 58 | 0 / 43 | | | | | | | | |
| Resistant A. baumannii | 0 / 405 | | | | | | | | | |
| Ourante-Mangoni 2013 ²⁸ | 0 / 105 | 0 / 104 | | | | | | | | |
| Pulmanory infection Parry 1977 ⁴⁸ | 7/14 | 7/14 | | 1.00 (0.23 to 4.40) | | | | | | |
| Pneumonia, sepsis, peritonitis | | | | | | | | | | |
| Cometta 1994 ²³ | 8 / 142 | 13 / 138 | +- | 1.74 (0.70 to 4.34) | | | | | | |
| Aultidrug resistant typhiod fe | | | | | | | | | | |
| ² arry 2007 ⁴⁹ | 0 / 125 | 0 / 67 | | | | | | | | |
| Gram-negative resistant BSI, Pogue 2021 ⁵¹ | pneumoni 23 / 191 | ia 16 / 189 | - | 0.68 (0.34 to 1.32) | | | | | | |
| Gram-negative hopsital acqui | ired infecti | | | 0.00 (0.0110 1.02) | | | | | | |
| Rubinstein 1995 ⁵³ | 12 / 261 | 14 / 230 | + | 1.34 (0.61 to 2.97) | | | | | | |
| E. coli | | | | | | | | | | |
| lack 1982 ²¹ | 5/10 | 0 / 10 | | 0.05 (0.00 to 1.03) | | | | | | |
| Cholangitis Gerecht 1989 ³⁰ | 0/24 | 0/22 | | | | | | | | |
| Carpenem resistant infections | | 0122 | | | | | | | | |
| Jarpenem resistant intections Dickstein 2020 ²⁶ | ; 10/106 | 12 / 108 | + | 1.20 (0.49 to 2.91) | | | | | | |
| | | | Į | | | | | | | |
| | | | | | | | | | | |
| otal (95% CI) | 181 / 262 | 1 176 / 2433 | • • | 1.23 (0.68 to 2.25) | | | | | | |
| | | | • | | | | | | | |
| otal (95% CI) | | | antibiotics Favors fe | | | | | | | |

Figure 3. Forest plot of acquisition of bacterial resistance stratified by the reason antibiotics were administered. The coloring indicates the number of antibiotics that were compared in each study. A) The overall pooled LOR of all included studies. B) The pooled LOR of studies with at least one antibiotic in common in the treatment arms. UTI stands for urinary tract infection, MRSA for

methicillin-resistant *Staphylococcus aureus*, MAC for *Mycobacterium avium* complex, and BSI for blood stream infection.

Table 1. Overview of the 42 RCTs or quasi-RCTs included in the systematic review and meta-analysis. The underlined antibiotics indicate that resistance measurements were made for this antibiotic, reported and extractable from the studies. Justification for resistance outcome extraction is given in SI table S1.

| Study | Type Of Study | Focused pathogen/ Reason for antibiotic treatment | Objective(S) | ANTIBIOTICS USED IN STUDY ARMS | | EXPLICIT DEFINITION OF RESISTANCE OUTCOME | SECONDARY OUTCOMES EXTRACTED |
|----------------------------------|------------------|---|---|---|--|---|--------------------------------------|
| | | | | LESS ANTIBIOTICS | MORE ANTIBIOTICS | | |
| Bender et al. (1979)(20) | RCT | Infection prophylaxis for patients with acute leukemia or malignant lymphomas receiving remission induction chemotherapy | Tolerance, suppression of microbial flora, protection against colonisation and infection | <u>Gentamicin</u> | <u>Gentamicin</u> , and vancomycin | no | All-cause mortality |
| Black et al. (1982)(21) | RCT | enterotoxigenic <i>Escherichia coli</i> (ETEC) | Compare two treatments options against ECET. | <u>Trimethoprim</u> | <u>Trimethoprim,</u> and sulfamethoxazole | no | - |
| Chaisson et al. (1997)(22) | RCT | MAC | Safety and activity | <u>Clarithromycin</u> , and ethambutol | <u>Clarithromycin,</u> <u>ethambutol</u> , and clofazimine | no | All-cause mortality |
| Cometta et al. (1994)(23) | RCT | Nosocomial pneumonia, nosocomial | Clinical efficacy and tolerance, emergence of | Imipenem | Imipenem, and netilmicin | no | Mortality attributable to infection, |

| | | sepsis, or severe diffuse peritonitis | resistance and risk of superinfection | | | | treatment failure, treatment failure due to a change of resistance against the study drugs |
|---|-----|--|---|--|---|-----|--|
| Dawson e al. (2015)(24) | | Mtb | Efficacy, and safety | <u>Moxifloxacin,</u> pretomanid, and p <u>yrazinamide</u> | <u>Isoniazid,</u> rifampicin, <u>pyrazinamide</u> , and ethambutol | no | Proportion of patients with alterations of the prescribed treatment due to adverse events |
| Dekker et al. (1987)(25) | | Prophylaxis for acute nonlymphocytic or lymphocytic leukemia | Efficacy of protecting against infections | <u>Ciprofloxacin</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | All-cause mortality, mortality attributable to infection, acquisition of resistance against non-administered antibiotics |
| Dickstein et al. (2019)(26) | RCT | Carbapenem resistant, colistin- susceptible, and gram-negative infections | Development of colistin resistance (secondary outcome of a clinical trial) | <u>Colistin</u> | Colistin, and meropenem | yes | All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events |
| Dubé et al (1997)(27) | | MAC | Risk of recrudescent MAC bacteraemia, emergence of resistance to clarithromycin. | <u>Clarithromycin</u> , and clofazimine | <u>Clarithromycin</u> , clofazimine, and ethambutol | no | All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events |
| Durante- Mangoni et al. (2013)(28) | RCT | Extensively drug resistant Acinetobacter baumannii | Mortality | <u>Colistin</u> | <u>Colistin</u> , and rifampicin | yes | All-cause mortality, mortality attributable to infection, treatment failure |
| Fournier et al. (1999)(29) | RCT | MAC | Efficacy and tolerance. | <u>Clarithromycin</u> , ethambutol | <u>Clarithromycin</u> , ethambutol, and clofazimine | no | All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events |
| Gerecht e al. (1989)(30) | | Cholangitis | Compare a single drug treatment to a two-drug treatment. | Mezlocillin | Ampicillin <u></u> , and <u>gentamicin</u> | yes | All-cause mortality, treatment failure as reported in each study, treatment failure due to a change of resistance against the study |

drugs

| Gibson et al. (1989)(31) | RCT | Febrile neutropenia | Efficacy and side effects | <u>Ceftazidime</u> | <u>Azlocillin</u> , and <u>amikacin</u> | no | All-cause mortality, mortality attributable to infection, proportion of patients with alterations of the prescribed treatment due to adverse events, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics |
|------------------------------------|-----|--|---|-----------------------|---|-----|---|
| Haase et al. (1984)(32) | RCT | UTI | Efficacy, tolerance, and safety | <u>Norfloxacin</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | Treatment failure, acquisition of resistance against non- administered antibiotics |
| Hartbarth et al. (2015)(33) | RCT | MRSA | Assess the non-inferiority of a multiple drug treatment in comparison of a single drug treatment. | <u>Linezolid</u> | <u>Trimethoprim</u> , <u>sulfamethoxazole</u> , and <u>rifampicin</u> | no | All-cause mortality, mortality attributable to infection, treatment failure |
| Hodson (1987)(34) | RCT | Cystic fibrosis patients with <i>P.</i> aeruginosa | Compare an oral one drug treatment to an intravenous two drug treatment. | <u>Ciprofloxacin</u> | <u>Azlocillin</u> , and <u>gentamicin</u> | no | - |
| Hoepelma n et al. (1988)(35) | RCT | Serious bacterial infections | Emergence of resistance of fecal flora | <u>Ceftriaxone</u> | Cefuroxime, and gentamicin | no | Proportion of patients with alterations of the prescribed treatment due to adverse events |
| Hultén et al. (1997)(36) | RCT | H. pylori | Antibacterial efficacy, emergence of clarithromycin resistance. | <u>Clarithromycin</u> | Clarithromycin, and lymecycline | no | - |
| Iravani et al. (1981)(37) | RCT | Acute UTI | Efficacy, treatment effects on fecal flora, resistance emergence in the infecting pathogen | <u>Nalidixic acid</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | - |
| Jacobs et al. (1993)(38) | RCT | Bacterial infections in neutropenic children | Efficacy and safety, tolerance, emergence of resistance and risk of superinfection | <u>Ceftazidime</u> | <u>Ceftazidime</u> , and <u>tobramycin</u> | yes | All-cause mortality, treatment failure, treatment failure due to a change of resistance against the study drugs |

| Jo et al. (2021)(39) | RCT | Determine impact of antibiotics on healthy skin microbiota | Investigate short and long term of the skin microbiome | <u>Doxcycycline</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | - |
|--|-----------|--|--|--|---|----|---|
| Macnab et al. (1994)(40) | Quasi-RCT | Mtb | Efficacy, primary drug resistance, bacteriological conversion rates, compliance, and side effects | <u>lsoniazid</u> , and <u>rifampicin</u> | <u>Isoniazid,</u> <u>rifampicin</u> , and <u>ethambutol</u> | no | Proportion of patients with alterations of the prescribed treatment due to adverse event |
| Markowit z et al. (1992)(41) | RCT | S. aureus | Efficacy and safety | <u>Vancomycin</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events |
| Mavroma nolakis et al. (1997)(42) | RCT | Recurrent UTIs | Effect on the aerobic bowel flora, frequency of resistant strains in the fecal flora during and after treatment. | <u>Norfloxacin</u> , or <u>Nitrofurantoin</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | - |
| May et al. (1997)(43) | RCT | MAC | Clinical and bacteriological efficacy, safety, tolerability | <u>Clarithromycin</u> , and clofazimine | <u>Clarithromycin</u> , rifabutin, and ethambutol | no | All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events |
| Mc Carty et al. (1988)(44) | RCT | Cystic fibrosis patients with <i>P.</i> aeruginosa | Safety, pharmacokinetics of a high-dose singe drug treatment, the effectiveness | <u>Piperacillin</u> | <u>Piperacillin</u> , and tobramycin | no | All-cause mortality, mortality attributable to infection |
| Menon et al. (1986)(45) | RCT | Acute UTI | Efficacy, selection of resistance in Enterobacteriaceae | <u>Trimethoprim</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | Acquisition of resistance against non-administered antibiotics |
| Miehlke et al. (1998)(46) | RCT | H. pylori | Effectiveness, tolerability | <u>Amoxicillin</u> | <u>Clarithromycin,</u> and metronidazole | no | Proportion of patients with alterations of the prescribed treatment due to adverse events |

| Parras et al. (1995)(47) | RCT | MRSA | Efficacy to eradicate, safety | <u>Mupirocin</u> | Sodium fusidate, trimethoprim, and sulfamethoxazole | no | All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events |
|-------------------------------------|-----------|---|---|--|---|-----|--|
| Parry et al. (1977)(48) | Quasi-RCT | Pulmonary infection | Effectiveness, treatment failure, treatment success, frequency of ticarcillin resistant organisms, influence of resistance on disease development | <u>Ticarcillin</u> | <u>Ticarcillin</u> , and gentamicin | no | - |
| Parry et al. (2007)(49) | RCT | Multidrug resistant typhoid fever | Efficacy | <u>Ofloxacin</u> , or <u>Azithromycin</u> | Ofloxacin, and Azithromycin | no | Treatment failure |
| Paul et al. (2015)(50) | RCT | MRSA | Test whether a two-drug treatment is non-inferior to a two-drug treatment. | <u>Vancomycin</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | yes | All-cause mortality, treatment failure, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics |
| Pogue et al. (2021)(51) | RCT | Gram negative resistant bloodstream infections or pneumonia | Assess superiority of a combination of colistin to monotherapy. | <u>Colistin</u> | <u>Colistin,</u> and meropenem | yes | All-cause mortality, treatment failure |
| Pujol et al. (2021)(52) | RCT | MRSA | Assess treatment success. | <u>Daptomycin</u> | <u>Daptomycin</u> , and <u>fosfomycin</u> | yes | All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events |
| Rubinstei n et al. (1995)(53) | RCT | Gram-negative hospital acquired infections | Efficacy, safety | <u>Ceftazidime</u> | <u>Ceftriaxone</u> , and <u>Tobramycin</u> | yes | All-cause mortality, mortality attributable to infection, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events |
| Schaeffer et al. (1981)(54) | RCT | UTI | Effectiveness, safety, incidence of resistance in faecal and vaginal flora | <u>Cinoxacin</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | Proportion of patients with alterations of the prescribed treatment due to adverse events |

| | | | before, and after treatment. | | | | |
|-----------------------------------|-----|--|--|--|---|-----|--|
| Schaeffer et al. (1985)(55) | RCT | UTI | Effectiveness, safety, incidence of resistance in fecal and vaginal flora before, and after treatment. | <u>Norfloxacin</u> | <u>Trimethoprim,</u> and <u>sulfamethoxazole</u> | no | - |
| Smith et al. (1999)(56) | RCT | P. aeruginosa | Efficacy | <u>Azlocillin</u> | <u>Azlocillin</u> , and <u>tobramycin</u> | no | Acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics |
| Stack et al. (1998)(57) | RCT | H. pylori | Efficacy, safety | <u>Clarithromycin</u> | <u>Clarithromycin</u> , and metronidazole, or amoxycillin | no | - |
| Walsh et al. (1993)(58) | RCT | MRSA | Efficacy of eradication, emergence of resistance, safety | <u>Novobiocin</u> , and <u>rifampicin</u> | <u>Rifampicin</u> , <u>trimethoprim</u> , and <u>sulfamethoxazole</u> | yes | Treatment failure, acquisition of resistance against non- administered antibiotics, emergence of resistance against non-administered antibiotics |
| Winston et al. (1986)(59) | RCT | Prophylaxis for hematological malignancy patients | Efficacy and safety | <u>Norfloxacin</u> | Vancomycin, and polymyxin | no | Mortality attributable to infection |
| Winston et al. (1990)(60) | RCT | Prophylaxis for hematological malignancy patients | Efficacy and safety | <u>Ofloxacin</u> | <u>Vancomycin</u> , and polymyxin | no | - |
| Wurzer et al. (1997)(61) | RCT | H. pylori | Effectiveness, emergence of resistance. | <u>Clarithromycin</u> | <u>Clarithromycin</u> , and <u>amoxycillin</u> | no | - |